Stock Analysis

MaaT Pharma Reports Full Year 2022 Earnings

Published
ENXTPA:MAAT
Source: Shutterstock

MaaT Pharma (EPA:MAAT) Full Year 2022 Results

Key Financial Results

  • Net loss: €13.7m (loss widened by 52% from FY 2021).
earnings-and-revenue-history
ENXTPA:MAAT Earnings and Revenue History April 1st 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

MaaT Pharma shares are up 5.3% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for MaaT Pharma (1 is a bit concerning!) that you should be aware of before investing here.

Valuation is complex, but we're helping make it simple.

Find out whether MaaT Pharma is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.